This trial is active, not recruiting.

Condition asthma
Sponsor Research in Real-Life Ltd
Collaborator British Lung Foundation
Start date May 2012
End date August 2014
Trial size 33370 participants
Trial identifier NCT02140671, ORO3112


Following on from a 10 year study conducted in Finland this study is designed to test the validity and sustainability of an enhanced asthma management model for the UK.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective

Primary Outcomes

Exacerbations reduction
time frame: 1 year

Secondary Outcomes

1. Increased assessment of patients with equivocal diagnoses and reduction of diagnostic doubt (also detailed under process outcomes)
time frame: 1 year
2. Hospitalisations ¬- number and rate - coded for: • Asthma • Lower respiratory conditions (including asthma), i.e. "asthma-related" events
time frame: 1 year
3. Inhaled corticosteroids adherence
time frame: 1 year
4. Referral rate of high-risk patients to local specialist
time frame: 1 year
5. British Asthma Guideline adherence: appropriate step-wise management of patients
time frame: 1 year

Eligibility Criteria

Male or female participants from 3 years up to 65 years old.

Inclusion Criteria: - Motivated and driven local champions in the area - High rates of hospital admissions (aged 3-65) - High asthma prevalence - High percentage of patients who have had an asthma review in the previous 15 months. Exclusion Criteria: -

Additional Information

Official title To Deliver a Pilot Project on Effective Interventions to Ensure: Diagnostic Accuracy, Management of Risk and Control and Self-management for Asthma Patients.
Principal investigator David Price
Description The British Lung Foundation (BLF) aims to work with the governments in the four UK nations to launch an asthma initiative designed to improve asthma management and outcomes. The project incorporates key learning from a 10 year programme in Finland designed to improve asthma care and cap healthcare costs for paediatric and adult populations. The Finland programme focused on accurate diagnosis, training and education of healthcare professionals and patients and early use of anti-inflammatory therapy. The programme successfully improved medication compliance, reduced asthma hospital admissions, reduced asthma-related benefit claims and reduced the overall cost of asthma to the Finnish Government. To test the validity and sustainability of an enhanced asthma management model for the UK, the BLF proposes to undertake a pilot initiative in England. The pilot will focus on: improving diagnostic accuracy through analysis of GP asthma registers; increasing asthma education among healthcare professionals; assessment of risk and control of patient's asthma; supportive self-management and education of people with asthma. It is anticipated that the pilot will lead to measureable and significant improvements in asthma management, including: - Reduced number of severe exacerbations (asthma hospitalisation, A&E attendance and oral steroid rescue) - Improved diagnostic accuracy (and reduction of diagnostic doubt) - Improved implementation of recognised asthma guidelines, including appropriate step wise management of patients The pilot will also aim to increase the proportion of patients on the asthma register with an asthma management plan and a recorded asthma control test therefore supporting higher levels of control, and will promote peer-to-peer health care professional asthma education and knowledge sharing to establish an asthma-training legacy. The pilot model will be sustainable and reproducible across England and the devolved nations (Scotland, Wales and Northern Ireland). Whilst the core aspects of an agreed national model will be rolled out across the pilot site, it will be tailored and refined through local collaboration (primary care, secondary care and commissioners) to help attain local targets in line with regional differences, needs and priorities. Results from the pilot will be reported 15 months after project initiation on site (July/August 2014)
Trial information was received from ClinicalTrials.gov and was last updated in May 2014.
Information provided to ClinicalTrials.gov by Research in Real-Life Ltd.